search button
Open Access

Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors

  • Authors:
    • Eriko Katsuta
    • Malgorzata Gil-Moore
    • Justine Moore
    • Mohamed Yousif
    • Alex A. Adjei
    • Yi Ding
    • Justin Caserta
    • Carmen M. Baldino
    • Kelvin P. Lee
    • Irwin H. Gelman
    • Kazuaki Takabe
    • Mateusz Opyrchal

  • View Affiliations

  • Published online on: August 3, 2022     https://doi.org/10.3892/ijo.2022.5404
  • Article Number: 114

  • Copyright: © Katsuta et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Proviral integration of Moloney virus 2 (PIM2) is a pro‑survival factor of cancer cells and a possible therapeutic target in hematological malignancies. However, the attempts at inhibiting PIM2 have yielded underwhelming results in early clinical trials on hematological malignancies. Recently, a novel pan‑PIM inhibitor, JP11646, was developed. The present study examined the utility of targeting PIM2 in multiple solid cancers and investigated the antitumor efficacy and the mechanisms of action of JP11646. When PIM2 expression was compared between normal and cancer tissues in publicly available datasets, PIM2 was found to be overexpressed in several types of solid cancers. PIM2 ectopic overexpression promoted tumor growth in in vivo xenograft breast cancer mouse models. The pan‑PIM inhibitor, JP11646, suppressed in vitro cancer cell proliferation in a concentration‑dependent manner in multiple types of cancers; a similar result was observed with siRNA‑mediated PIM2 knockdown, as well as an increased in cell apoptosis. By contrast, another pan‑PIM inhibitor, AZD1208, suppressed the expression of downstream PIM2 targets, but not PIM2 protein expression, corresponding to no apoptosis induction. As a mechanism of PIM2 protein degradation, it was found that the proteasome inhibitor, bortezomib, reversed the apoptosis induced by JP11646, suggesting that PIM2 degradation by JP11646 is proteasome‑dependent. JP11646 exhibited significant anticancer efficacy with minimal toxicities at the examined doses and schedules in multiple in vivo mice xenograft solid cancer models. On the whole, the present study demonstrates that PIM2 promotes cancer progression in solid tumors. JP11646 induces apoptosis at least partly by PIM2 protein degradation and suppresses cancer cell proliferation in vitro and in vivo. JP11646 may thus be a possible treatment strategy for multiple types of solid cancers.
View Figures
View References

Related Articles

Journal Cover

October-2022
Volume 61 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 5.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 11.4
  • CiteScore Rank: Q1: #40/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 1.125
  • SCImago Journal Rank (SJR): 1.105
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Katsuta E, Gil-Moore M, Moore J, Yousif M, Adjei AA, Ding Y, Caserta J, Baldino CM, Lee KP, Gelman IH, Gelman IH, et al: Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors. Int J Oncol 61: 114, 2022
APA
Katsuta, E., Gil-Moore, M., Moore, J., Yousif, M., Adjei, A.A., Ding, Y. ... Opyrchal, M. (2022). Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors. International Journal of Oncology, 61, 114. https://doi.org/10.3892/ijo.2022.5404
MLA
Katsuta, E., Gil-Moore, M., Moore, J., Yousif, M., Adjei, A. A., Ding, Y., Caserta, J., Baldino, C. M., Lee, K. P., Gelman, I. H., Takabe, K., Opyrchal, M."Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors". International Journal of Oncology 61.4 (2022): 114.
Chicago
Katsuta, E., Gil-Moore, M., Moore, J., Yousif, M., Adjei, A. A., Ding, Y., Caserta, J., Baldino, C. M., Lee, K. P., Gelman, I. H., Takabe, K., Opyrchal, M."Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors". International Journal of Oncology 61, no. 4 (2022): 114. https://doi.org/10.3892/ijo.2022.5404